Five-Year Update of an Expanded Phase II Study of Dose-Dense and -Intense Doxorubicin, Paclitaxel and Cyclophosphamide (ATC) in High-Risk Breast Cancer-Reference-Cited by-同舟云学术

Five-Year Update of an Expanded Phase II Study of Dose-Dense and -Intense Doxorubicin, Paclitaxel and Cyclophosphamide (ATC) in High-Risk Breast Cancer

Published:2005 Issue:5 Volume:69 Page:372-383
ISSN:0030-2414
Container-title:Oncology
language:en
Short-container-title:Oncology

Author:

Abu-Khalaf Maysa M.,Windsor Stephen,Ebisu Keita,Salikooti Saritha,Ananthanarayanan Gowri,Chung Gina G.,DiGiovanna Michael P.,Haffty Bruce G.,Abrams Martin,Farber Leonard R.,Hsu Arlene D.,Reiss Michael,Zelterman Daniel,Burtness Barbara A.

Publisher

S. Karger AG

Subject

Cancer Research,Oncology,General Medicine

Reference41 articles.

1. Relation of tumor size, lymph node status, and survival in 24,740 breast cancer cases

2. Patterns of Relapse and Survival in Operable Breast Carcinoma with Positive and Negative Axillary Nodes

3. Adjuvant Cyclophosphamide, Methotrexate, and Fluorouracil in Node-Positive Breast Cancer — The Results of 20 Years of Follow-up

4. Sledge G: Advances in monoclonal antibody therapy for breast cancer: targeting Her-2 in the adjuvant setting. Scientific Symposium, Annual Meeting of the American Society of Clinical Oncology, 2005.

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Association of Aromatase Inhibitor-Induced Musculoskeletal Symptoms with Central Sensitization-Related Symptoms: A Cross-Sectional Study;Breast Care;2024

2. Taxane-induced arthralgia and myalgia: A literature review;Journal of Oncology Pharmacy Practice;2016-06-23

3. Comparative study of the toxicity of 5-fluorouracil-adriamycin-cyclophosphamide versus adriamycin-cyclophosphamide followed by paclitaxel in carcinoma breast;Indian Journal of Cancer;2011

4. Oral Mucositis;Supportive Care in Cancer Therapy;2008-09-22

5. Risk factors for joint symptoms in patients enrolled in the ATAC trial: a retrospective, exploratory analysis;The Lancet Oncology;2008-09